Assess whether the primary endpoint will survive FDA scrutiny from biosimilar

SITUATION FDA Response and Labeling work in a safety team sitting on a new disproportionate signal now turns on the primary endpoint will because a pediatric ethicist objecting to the proposed design put biosimilar analytical similarity report in play. Pharmacovigilance medical reviewer should say what biosimilar analytical similarity report proves.

DECISION Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Pharmacovigilance medical reviewer can defend Proceed under protocol from biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design in a Pharma & Life Sciences challenge. 2. Pharmacovigilance medical reviewer cannot defend Proceed under protocol from biosimilar analytical similarity report; Pause the pathway is what the extract actually supports after a pediatric ethicist objecting to the proposed design. 3. A pediatric ethicist objecting to the proposed design never reached the population in biosimilar analytical similarity report — reopen intake, do not close the primary endpoint will. 4. Two facts in biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design conflict for pharmacovigilance medical reviewer; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read biosimilar analytical similarity report against a pediatric ethicist objecting to the proposed design and write the one fact that would move the primary endpoint will for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a pediatric ethicist objecting to the proposed design, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal.